143 related articles for article (PubMed ID: 26331791)
1. Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients.
Godoy AL; Rocha A; da Silva Souza C; Lanchote VL
J Clin Pharmacol; 2016 May; 56(5):567-75. PubMed ID: 26331791
[TBL] [Abstract][Full Text] [Related]
2. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
[TBL] [Abstract][Full Text] [Related]
5. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
[TBL] [Abstract][Full Text] [Related]
6. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).
Lloret-Linares C; Daali Y; Chevret S; Nieto I; Molière F; Courtet P; Galtier F; Richieri RM; Morange S; Llorca PM; El-Hage W; Desmidt T; Haesebaert F; Vignaud P; Holtzmann J; Cracowski JL; Leboyer M; Yrondi A; Calvas F; Yon L; Le Corvoisier P; Doumy O; Heron K; Montange D; Davani S; Déglon J; Besson M; Desmeules J; Haffen E; Bellivier F
BMC Pharmacol Toxicol; 2017 Nov; 18(1):70. PubMed ID: 29115994
[TBL] [Abstract][Full Text] [Related]
7. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Reis M; Lundmark J; Björk H; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
[TBL] [Abstract][Full Text] [Related]
10. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
[TBL] [Abstract][Full Text] [Related]
14. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
[TBL] [Abstract][Full Text] [Related]
16. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
20. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
